AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03735927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spot monitoring device, excl. Sham
Description: During the control phase the 'care as usual' regarding delirium screening is studied. During the intervention phase the DeltaScan will be studied as screening method for delirium. During the intervention phase the DeltaScan will be used on the exact same moments, i.e. same time and same amount of measures per day, as the screening methods used in the 'care as usual'.
Study NCT00665899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer-Focused Relationship Enhancement
Description: Couples meet individually with a health educator for 6 sessions to learn about ways to support each other and communicate about breast cancer related issues.
Study NCT00665899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple's Cancer Education
Description: Couples meet individually with a health educator for 6 sessions to discuss the medical aspects of breast cancer and treatment options.
Study NCT02242084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenuse Alteplase
Study NCT00676676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Testosterone atch delivering 300mcg daily for 8-weeks
Study NCT03753646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactating allowance and psycho social stimulation
Description: Mothers will receive lactating allowance and psycho social stimulation
Study NCT02316535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: adjuvant chemotherapy;
Study NCT02316535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: adjuvant chemotherapy;
Study NCT00873977 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP (REMstar (Respironics))
Description: Pressure-relief CPAP treatment may reduce the sensation of breathing against high pressure without causing the upper airways to collapse and improve adherence.
Study NCT04066270 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: video nystagmography
Description: routine test battery applied to all cochlear implant candidates
Study NCT01048762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical exercise and dyspnoea counseling
Description: Exercise training in group, 1 hour once a week for 10 weeks, based om aerobic exercises 60-80% of VO2 max (Borg 11-12), resistance training and dyspnea counseling. Participants are urge to exercise training for at least twice a week.
Study NCT01048762 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: home training
Description: one instruction in home based exercise training
Study NCT01048762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home training
Description: one instruction in home based exercise training
Study NCT00326209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encapsulated Mesalamine Granules (eMG)
Description: eMG capsules will be administered per dose and schedule specified in the arm.
Study NCT01278745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper)
Study NCT01278745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)
Study NCT04608227 — intervention group
Intervention type: DEVICE
Intervention: Clearsight monitoring
Description: Non invasive hemodynamic monitoring using a finger cuff Cardiac ultrasound performed to calculate Velocity - Time - integral (VTI) Both intervention are performed before and after a passive leg raising challenge.
Study NCT03121911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Training (IT)
Description: Each exercise session will consist of:~1. warm up (10 minutes)- stretches and calisthenics exercises of low to moderate intensity;~2. interval training (IT) - 30 minutes of IT performed in a cycle ergometer, divided into 6 levels of intensity based on the ventilatory anaerobic threshold (VAT) found in CPET: Level 1 - 5 minutes in moderate intensity, at 80% of power reached in VAT; Levels 2 and 4 - 5 minutes of moderate to high intensity, at 100% of VAT; Levels 3 and 5 - 5 minutes of moderate to high intensity, 110% of VAT; Level 6 - 5 minutes in moderate intensity, at 70% of VAT.~3. cooling down (10 minutes) - stretching, and breathing exercises. An CPET will be performed every four weeks to adjust the intensity of training.
Study NCT03121911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Description: The IMT session will take place just after the warm-up exercises and consist of 2 series of 12 inspirations with a 60% of Maximal Inspiratory Pressure (MIP) with the equipment POWERbreathe Plus Medic® (POWERbreathe International Ltd, Warwickshire, UK). The patient will be instructed to remain seated with a nasal clip during the IMT series to avoid nasal air leakage and will be asked to inhale quickly and deeply, as quickly as possible, with a 2 minute interval between series. The training load will be adjusted weekly by a new evaluation of MIP to maintain the intensity of the exercise within the proposed value.~All the others exercises will be identical between group 1 and 2.
Study NCT06215521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally
Study NCT06215521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT06215521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Administered orally
Study NCT02371226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGT-181 (HIRMAb-IDUA)
Description: intravenous infusion over 3-4 hours
Study NCT01843842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergoferon
Description: Safety and Efficiency of liquid dosage form
Study NCT01843842 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Safety and Efficiency of liquid dosage form
Study NCT03668886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimodal exercise program
Description: warm-up, strengthening exercise, aerobic exercise, cool-down
Study NCT01239550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Detemir
Description: Subjects randomized to insulin detemir treatment group will receive the basal insulin in a 3 mL. Flex Pen® containing 300 units of insulin. insulin detemir once daily administered with the evening meal (dinner) or at bedtime as add-on to their oral antihyperglycemia (see inclusion/exclusion criteria) meds throughout the 24 week treatment period. The goal of insulin therapy is to achieve near normoglycemia with a low rate of hypoglycaemic episodes.~Insulin injections will be given subcutaneously preferably in the thigh or abdomen.
Study NCT00433914 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB
Description: One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
Study NCT00433914 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV
Description: One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
Study NCT03639870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model iS3 three-stent trabecular micro-bypass system
Description: Provided in Arm/Group descriptions.
Study NCT01886573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC
Study NCT01886573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO
Study NCT01886573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01886573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01886573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT01977599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message Reminder for Breast Screening Appointment
Description: Non-clinical/administrative.
Study NCT03257670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% Topical Lidocaine Gel
Description: This group will be given 4% topical lidocaine gel to take home. The patient will apply the 4% lidocaine gel to the outside and opening of the vagina for 3 minutes before vaginal penetration. The patient will continue using the numbing gel prior to vaginal penetration for the extent of the study (3 months).
Study NCT03257670 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2RE fractional laser therapy
Description: This group will undergo vaginal CO2 laser therapy for a total of three (3) treatments with one month between treatments.
Study NCT03098849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buteyko Breathing Technique
Description: Patients are trained in various exercises aiming at breath reduction and breath control as introduced by Dr. K. Buteyko
Study NCT06466447 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exposure and response prevention therapy
Description: Exposures and response prevention therapy (a type of cognitive-behavioral therapy for obsessive-compulsive disorder), delivered in real-time by therapists remotely via video. The treatment was augmented by between-session text messaging.
Study NCT04828070 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: all participants followed for clinical data for one year, vital status check at 5 years
Study NCT01169298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide: 25mg daily on day 1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort, or 35 mg daily of each 28 days (3rd cohort)
Study NCT02691975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3680
Description: SHR3680 is administrated orally, qd, 28 days as one cycle. Patients may continue SHR3680 until disease progression or unacceptable toxicity.
Study NCT01118273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg
Description: Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
Study NCT01118273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium 440 mg (BAYH6689)
Description: Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.
Study NCT01118273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg
Description: One dose of naproxen sodium 220 mg plus diphenhydramine 50 mg
Study NCT01118273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium 220 mg (BAYH6689)
Description: Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.
Study NCT01118273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPH 50mg
Description: Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.
Study NCT01118273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg / Diphenhydramine citrate 76 mg
Description: Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.
Study NCT03574675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Altitude (FiO2: 15.1)
Description: Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask.
Study NCT03574675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shamed Hypoxia (FiO2: 20.9)
Description: Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask.
Study NCT00496730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin (+) ezetimibe
Description: simvastatin (+) ezetimibe 10/20 mg ; tablet, once daily, 8 Weeks
Study NCT00496730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: atorvastatin
Description: atorvastatin 10 mg; tablet, once daily, 8 Weeks
Study NCT04383873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training by means of Armeo Spring device
Description: This patients group receive 40 experimental sessions. Each session is based on 30 min by using Armeo Spring device.
Study NCT04383873 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current treatment based on conventional therapy
Description: All the patients enrollment in the study receive 30 min of conventional therapy during 40 sessions.
Study NCT04383873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Current treatment based on conventional therapy
Description: All the patients enrollment in the study receive 30 min of conventional therapy during 40 sessions.
Study NCT04383873 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Additional treatment based on conventional therapy
Description: This intevention was added for providing the same amount of therapy than those patients randomly enrolled in the intervention group. So, patients in the control group receive other 30 min of conventional therapy added on current treatment during 40 sessions.
Study NCT00800436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be administered IV or SC at various dosages (depending upon the cohort to which the participant is assigned) on Day 1.
Study NCT02004262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX Pancreas Vaccine
Study NCT02004262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207
Study NCT02004262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Investigator's choice of one of the following commercially available products: gemcitabine; capecitabine; fluorouracil with or without leucovorin; irinotecan; or erlotinib.
Study NCT02004262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT02068742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: battery neuropsychological tests
Description: Application of the scores will be on the day 0 (the day before the surgery), day 2 and day 4 (after the surgery).
Study NCT02068742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: battery neuropsychological tests
Description: Application of the scores will be on the day 0 (the day before the surgery), day 2 and day 4 (after the surgery).
Study NCT04240015 — intervention group
Intervention type: OTHER
Intervention: Oral-Dental Health-Related Quality of Life-United Kingdom (OHRQoL-UK) scale
Description: It consists of 4 different categories and 16 questions evaluating the effects of OHRQoL in positive and negative areas. These categories are as follows; symptoms (2 questions), physical status (5 questions), psychological status (5 questions), social status (4 questions) ' Questions on the OHRQoL-UK scale were scored using the Likert-type scale as 'very bad effect-score 1, bad effect-score 2, no effect-score 3, good effect-score 4, very good effect-score 5. The scores obtained from all questions were summed to give the scores of the 4 sub-categories separately and the total OHRQoL score. A higher total score indicates a higher OHRQoL.
Study NCT03076385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAL-506440
Description: Escalating dose levels
Study NCT03076385 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00914251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hesperidin
Description: Administration of oral Hesperidin, 500 mg/daily
Study NCT00914251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of oral Placebo, 500 mg/daily
Study NCT02263274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (TDCS)
Description: Conventional tDCS and low-frequency tACS are commonly administered at a current intensity of 2 mA or less
Study NCT02124239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate
Study NCT02583906 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CPAP
Description: Treatment with CPAP for six months in the CPAP arm.
Study NCT03823066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coach Pepper
Description: Robot Peppers's height is 1.20 meters and it weighs 28 kilograms. Pepper will be called Coach Pepper, because it is connected, via web interfaces, with a theratainment app including cognitive and physical training
Study NCT03478553 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Blood draw
Study NCT03478553 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Pulmonary Fibrosis Questionnaire
Study NCT00841802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 30mg once daily x 5 days
Study NCT04086823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RZL-012
Description: Subcutaneous injection to the submental fat area
Study NCT04086823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00625209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebos
Description: placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of fludrocortisone given through the nasogastric tube once a day for seven days plus placebo of activated protein C given as a continuous infusion for 96 hours
Study NCT00625209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone and fludrocortisone and placebo
Description: hydrocortisone will be given as 50mg iv bolus every 6 hours for seven days and a tablet of 50µg of fludrocortisone will be given once a day via the nasogastric tube for seven days and a placebo of activated protein C will be given as a continuous infusion for 96 hours
Study NCT00625209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human activated protein C and placebos
Description: activated protein C will be given as a continuous infusion at a dose of 24 µg/kg/h four 96 hours and hydrocortisone placebo as an iv bolus every 6 hours and fludrocortisone placebo once a day through the gastric tube will be given for seven days
Study NCT00625209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human activated protein C and hydrocortisone and fludrocortisone
Description: 96 hours continuous infusion of 24µg/kg/h of activated protein C plus seven day treatment with 50mg iv bolus of hydrocortisone every 6 hours and 50µg of fludrocortisone via the nasogastric tube once a day
Study NCT01515761 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postero-lateral
Description: A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or postero-lateral area of the LV based on pre-procedure randomization.
Study NCT01515761 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antero-Lateral
Description: A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or antero-lateral area of the LV based on pre-procedure randomization.
Study NCT02970825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate to high intensity physical training
Study NCT02970825 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: Low intensity physical activity and relaxation
Study NCT03839173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human milk based human milk fortifier
Description: A human milk fortifier with added minerals made from donor human milk
Study NCT04071574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Administration of hCG (10.000IU) for ovulation triggering
Study NCT04071574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: Administration of Menotropin (hMG / FSH and LH at a 1:1 ratio) (150-225IU/day)
Study NCT04071574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GNRH-A Triptorelin
Description: Administration of Triptorelin (0.1mg/day)
Study NCT04071574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: Administration of cetrorelix (cetrotide) or ganirelix (orgulatron) (0.25mg/day)